Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05182476 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

A Phase 2 study, sponsored by Neurocrine Biosciences.

Terminated
Registry status
Phase 2
Development phase
216
Enrollment target

NCT05182476: Clinical Trial Phase 2 study, sponsored by Neurocrine Biosciences.

NCT05182476 is a Phase 2 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 216 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05182476, a Phase 2 study, was terminated before completion, sponsored by Neurocrine Biosciences.

TERMINATED
Registry status
Phase 2
Development phase
216 participants
Enrollment target

Study Summary

Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.

Interventions

  • DRUG Placebo
  • DRUG Luvadaxistat

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2021-12-07
Est. Completion 2024-10-14
Phase Phase 2
Neurocrine Biosciences

65 total trials

Why NCT05182476 stopped before completion

NCT05182476 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05182476 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05182476 about?

NCT05182476 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia". Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.

What is the current status of trial NCT05182476?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2021-12-07. Estimated completion is 2024-10-14.

What interventions are being tested in trial NCT05182476?

The interventions under investigation include: Placebo (DRUG), Luvadaxistat (DRUG).

Who is sponsoring clinical trial NCT05182476?

This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05182476's enrollment target sits among peer trials

216 286th of 2000 higher than 1,712 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02609685 · 216 participants · NA

    Active Surveillance of Papillary Thyroid Microcarcinoma

  • NCT04994873 · 216 participants · NA

    Skills to Enhance Positivity in Suicidal Youth

  • NCT05264779 · 216 participants · NA

    The Periviable GOALS Decision Support Tool

  • NCT05434130 · 216 participants · Phase 2

    Modulating Exercise Dosage to Improve Concussion Recovery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05182476, the US trial registry maintained by the National Library of Medicine. NCT05182476 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.